ArticleJournal of managed care & specialty pharmacy2022
Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases.
Article in Journal of managed care & specialty pharmacy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Healthcare resource use and costs following RSV-related hospitalizations among US adults aged 50 years and older.Human vaccines & immunotherapeutics · 2026Article
- Incidence of respiratory syncytial virus and influenza: A Danish nationwide cohort study.Human vaccines & immunotherapeutics · 2026Article
- Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- Respiratory syncytial virus infection in adults: Clinical manifestations, outcomes, and vaccines.Journal of the Chinese Medical Association : JCMA · 2026Review
- Chemically Engineered Sulfates of Lasiodiplodan: Antioxidant, Antimicrobial, and Antirespiratory Syncytial Virus (RSV) Activities.ACS omega · 2026Article
- The Impact of Pulmonary Hypertension on Hospitalization Risk in Adults with Respiratory Syncytial Virus Infection.Biomedicines · 2025Article
- Burden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- Economic burden of cardiorespiratory hospitalizations associated with respiratory syncytial virus among United States adults in 2017-2019.Human vaccines & immunotherapeutics · 2024Article
- Incidence of RSV in Adults: A Comprehensive Review of Observational Studies and Critical Gaps in Information.The Journal of infectious diseases · 2024Review
- Immediate post-discharge care among US adults hospitalized with respiratory syncytial virus infection.BMC pulmonary medicine · 2024Observational
- Article
- Attributable Cost of Adult Respiratory Syncytial Virus Illness Beyond the Acute Phase.Open forum infectious diseases · 2024Article
- Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate.Vaccines · 2023Article
- Respiratory Syncytial Virus-Related Complications and Healthcare Costs Among a Medicare-Insured Population in the United States.Open forum infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.